How to Evaluate a Regenerative Medicine Clinic

The regenerative medicine space attracts good clinicians. It also attracts a lot of sales. From a patient's perspective, the hard part is that both can have the same waiting room aesthetic, the same beautiful website, and the same confident pitch. The differences are visible if you know where to look.

This guide is the checklist I'd want someone in my own family to use before paying any clinic a five-figure deposit. I run a regenerative medicine clinic in Southlake, so I'm not a disinterested third party. I do think the questions here are the right ones to ask, and that you should ask them of us, too. Nothing in this checklist is something we'd object to answering.

The questions below are organized by what they test. Some test whether the clinic does diagnostic medicine. Some test whether they understand their own product. Some test the regulatory and credentialing baseline. Some test the operator. A few are about pricing transparency and the willingness to say no, which together separate practices from sales operations more cleanly than anything else.

A short history of why this matters

The contemporary regenerative medicine consumer market in the United States began roughly fifteen years ago with a handful of clinics offering bone marrow and adipose-derived cell injections for orthopedic and systemic indications. Several waves of FDA enforcement action have shut down or curtailed the most egregious operations, particularly around adipose-derived cells processed with collagenase and around products marketed for unapproved drug indications (ALS, Parkinson's, multiple sclerosis, autism). The current market has cleaned up around the edges but still contains significant variation in clinical practice quality, sourcing rigor, and regulatory compliance.

The published academic critique of the consumer stem cell market is worth reading if you have time. Leigh Turner and Paul Knoepfler in particular have published systematic surveys of clinics' marketing claims and the gap between those claims and the actual evidence base. The Knoepfler lab blog (The Niche) is a useful patient-facing resource even when you disagree with their positions.

You don't need to read any of that to be a smart consumer. You need to ask the right questions on the first phone call.

1. Did anyone look at your imaging before quoting a protocol?

This is the single fastest filter.

Real clinical work goes: history and exam, imaging review, sometimes labs, then a written plan. A clinic that quotes you a "stem cell package" over the phone or before reviewing your MRI is not practicing medicine. They're selling a product. The product may even work, occasionally. But the process is wrong, and a wrong process eventually produces wrong answers.

If you don't have recent imaging, a credible clinic will either order it or tell you what they need before pricing anything. They won't quote a number first.

Some clinics get around this filter by offering a "free consultation." During the consultation, after you've walked in the door and committed an hour of your time, the imaging review happens and the protocol gets recommended. That's better than a phone quote, but watch for whether the "free" consultation has a price ceiling on protocol recommendations that mysteriously goes up if you don't decide that day. The high-pressure version of this is the hallmark of a sales-driven clinic.

At Apex, our consultation is paid. The fee is the same whether you become a treatment patient or not. We do this on purpose: it removes any incentive for us to recommend a protocol to a patient who isn't a candidate. The structure shapes the practice.

2. Who is doing the injection?

Specifically: is the person doing the injection a licensed physician with documented training in image-guided injection of the structure being treated?

In Texas, mid-level providers (physician assistants, nurse practitioners) can inject under physician supervision, but for a joint or spine procedure costing thousands of dollars, you should know:

Who is holding the needle. Names, not job titles. If the front desk says "one of our providers," ask which one.

What their formal training in this procedure is. There's a difference between someone who learned image-guided injection during a weekend course and someone who completed a fellowship in interventional pain or musculoskeletal medicine. The skill gap shows up in placement accuracy, which is the entire ballgame for regenerative procedures.

Whether the supervising physician is on site during the procedure. In some clinic models, the supervising physician signs the charts but isn't physically present. That structure is legal but worse for patient safety, especially for procedures where complications can occur.

How many of these procedures the operator has performed. There's no magic threshold, but if the answer is "we just started offering this last month," weigh that against your willingness to be early in the learning curve.

A clinic that bristles at this question is one to skip. You're allowed to ask who is going to be holding a needle inside your joint.

3. Is the injection image-guided?

For any joint, tendon, or spinal injection, ultrasound guidance is standard of care in 2026. The published literature on injection accuracy is unkind to blind injection: even experienced injectors miss the target in joints like the shoulder and hip more often than they think.

Ask: "Will this injection be done under ultrasound?" If the answer is "we usually do it by feel," that protocol is gambling with your money and your tissue. (More in why every Apex injection is image-guided.)

Some clinics will say "we use ultrasound to confirm placement." Confirm-placement is not the same as real-time guidance. The standard of care is real-time visualization of the needle tip throughout the procedure, with image documentation saved to the chart. If the clinic uses ultrasound only as an after-the-fact spot check, that's a softer version of blind injection.

4. What's the cell source, and who processed it?

If a clinic is offering stem cell therapy, they should be able to answer in plain English:

What tissue the cells come from (umbilical cord, bone marrow, adipose, Wharton's jelly, placental membrane, etc.).

Whether the cells are allogeneic (donor) or autologous (your own).

The processing facility's name, certification, and FDA registration status. Reputable cellular products come from tissue establishments registered with the FDA under 21 CFR 1271. The registration number is verifiable in FDA's public database.

Whether the product is shipped in lots with documentation. Real allogeneic products come with a certificate of analysis per lot: donor screening results, cell count, viability percentage, sterility testing.

The cell count per dose. A vague "we use the optimal dose" is not an answer. The dose should be a number, in units of viable cells per dose, documented on your treatment record.

If they hand you a marketing brochure instead of answering, that's the answer.

At Apex, we use screened allogeneic umbilical-derived MSCs and MSC-derived exosomes from FDA-registered processors. We can show you the documentation. We've explained why we don't use bone marrow or adipose-derived cells in a separate post.

5. Is the cell product FDA-compliant under 361 HCT/P?

The FDA divides human cellular and tissue-based products into two regulatory pathways. "361" products are minimally manipulated and used for homologous purposes; they don't require pre-market approval but must meet specific tissue establishment requirements. "351" products are considered drugs and require FDA approval, which almost none currently have for orthopedic indications.

A legitimate clinic should be able to tell you which pathway their product is in, and why. A clinic that handwaves this question, or claims their cells are "FDA approved" when they aren't, is either confused or evasive. Both are bad signs.

There is no FDA-approved orthopedic stem cell drug product. Any clinic marketing materials that use the phrase "FDA approved" to describe a stem cell injection are using language that's at best misleading. The accurate language is "the cell product is sourced from an FDA-registered tissue establishment under 361 HCT/P regulations."

The distinction sounds technical but matters in practice. Products that don't meet the 361 criteria but are sold as if they do are operating outside the regulatory framework. Several clinic networks have been shut down or warned by FDA over exactly this distinction. You don't want to be the patient who finds out about it after paying.

6. How many conditions does the clinic claim to treat?

A clinic that lists fifty conditions on their website (autism, MS, COPD, diabetes, Parkinson's, hair loss, Lyme, long COVID, every joint in the body) is selling. Real clinical work narrows. Apex treats specific orthopedic, neuro, and systemic indications where there's a defensible mechanism and reasonable evidence. We say no to a lot of things, including conditions where the cell biology might theoretically help, because "theoretical" isn't the same as "ready to bill a patient for."

Ask the clinic to name three conditions they would not treat with their protocol, and why. The answer tells you whether they're practicing inside an evidence base.

Be particularly wary of clinics treating neurodegenerative diseases (ALS, MS, Parkinson's, Alzheimer's) with intra-thecal or intra-venous stem cell protocols outside of registered clinical trials. The FDA has been explicit about its concerns here, and the published evidence does not support these protocols at consumer-market pricing.

Pediatric autism treatment with stem cells is another flag. The literature does not support routine clinical use, and the families seeking these treatments are often in difficult financial and emotional positions. Clinics that prey on this population are doing serious harm.

7. Is there a written protocol?

A written protocol is a one or two page document with:

• The indication, stated plainly
• The chosen modality and dose
• The injection site(s) and image-guidance plan
• The expected timeline for response
• Follow-up schedule and re-evaluation criteria
• A definition of what a treatment success and failure look like
• The cost

If you don't get a written protocol, you don't have a plan. You have a transaction.

You should also receive a clear informed consent document covering:

• The procedure being performed
• Realistic expected outcomes (no "miracle cure" language)
• Specific risks, both common and rare
• Alternative treatments including surgery
• The financial terms

Read the consent. Look specifically for language that promises results (which is a legal red flag) and language that disclaims any responsibility for outcomes (which is a different kind of red flag). Both are common in the regenerative space, and neither is what a real clinical consent should look like.

8. What does the clinic do when you fail?

Every regenerative protocol has non-responders. Anyone who tells you they have a 100% success rate is lying or doesn't track outcomes.

A real clinic has a path for the patients who don't respond. They re-evaluate. They consider alternate modalities. They refer to surgery if surgery is the right answer. They don't sell you a second round just to try again.

Ask: "What happens if I'm not better at 12 weeks?" The answer should include:

• A scheduled re-evaluation visit, often with the same physician
• Re-assessment of the imaging and clinical picture
• A decision tree that includes the possibility of "this protocol didn't work for you, here's what we'd consider next"
• A willingness to refer you to a surgeon or back to your primary clinician if that's the right answer
• No automatic upsell to a "boost dose" or "phase 2 of the package"

The wrong answer is "we'll just do another round." Defaulting to a second injection on a non-responder, without re-evaluating whether the protocol was the right tool in the first place, is malpractice with marketing on top.

9. Price transparency

Honest cash pricing is a credibility signal. Vague "investment levels" and "membership packages" are not.

A real clinic will tell you:

The cost per joint or per indication, in dollars.

What's included and what isn't (imaging, follow-up, second injections, image guidance fees if separately billed).

Their financing partner, if any, with stated APRs. Watch specifically for "promotional 0% APR" that resets to a high market rate after a teaser period. Read the financing terms before you sign.

Whether HSA or FSA funds apply.

Apex publishes pricing in the coverage, cost, and financing guide. If a clinic refuses to put a number on their protocol before you book a consultation, that's a tell.

A few specific pricing red flags:

"Memberships" priced at $5,000 to $25,000 per year, structured to make patients feel they're getting a deal but rarely producing real savings on actual care.

"Today-only" pricing that goes up if you don't decide at the consultation.

Bundled multi-joint packages priced higher than the sum of individual joint pricing would be, marketed as discounts.

Add-on "wellness" services (NAD, peptides, IV vitamin therapy) bundled into the regenerative package at significant markup, regardless of whether the patient needs them.

10. Willingness to say no

This is the most underrated signal in the space. A clinic that has ever said "this isn't the right protocol for you, here's what is" is a clinic doing medicine. A clinic where the answer is always "yes, you're a candidate" is a clinic doing marketing.

We publish examples of patients we've declined and what we recommended instead in Cases we turned away. Ask any clinic you're evaluating to do the same.

The follow-up question is: "Can you tell me about a patient you've recently declined to treat?" If they can't think of one, that's information. If they describe a patient and the reasoning sounds like a real clinical decision, that's also information.

Verifying credentials in five minutes

You can verify almost everything you need to know about a clinician in under five minutes, online, for free.

State medical board. In Texas, the Texas Medical Board website (tmb.state.tx.us) lets you look up any licensed physician. The lookup shows licensure status, specialty, training history, and any disciplinary actions. The same lookup exists in every state under that state's medical board website. Disciplinary actions don't always disqualify a physician, but they're context worth having.

NPI registry. Every healthcare provider in the United States has a National Provider Identifier. The NPI registry at npiregistry.cms.hhs.gov is searchable by name. Each provider's record lists their primary practice specialty, their practice address, and basic identification. A provider whose primary specialty in the NPI registry doesn't match the kind of work they're advertising is worth a closer look.

Board certification. The American Board of Medical Specialties has a free public lookup at certificationmatters.org. It tells you whether a physician is board-certified in their specialty and whether that certification is current. Board certification is not required to practice medicine, but its absence in a physician who claims it is a serious red flag.

Hospital affiliations. Active hospital privileges in the local market suggest the physician is in good standing with credentialing committees that have access to information you don't. A regenerative clinician with no hospital affiliation isn't necessarily a problem, but a clinician who claims hospital privileges they don't actually have is.

For Apex, you can verify Dr. Abdullah's credentials at the NPI registry (1124445259) and the Texas Medical Board's licensure verification page.

Clinics in networks vs solo practices

A category that confuses some patients: clinics operating under a national brand or franchise. Several regenerative medicine networks operate dozens or hundreds of locations across the country under shared marketing. The clinical quality across these networks varies enormously, because the physician at the location you visit may have very different training and judgment than the marketing implies.

Network membership isn't automatically a problem. Some networks support member clinics with strong protocols, shared continuing education, and good central sourcing. Others are essentially marketing engines selling franchise rights to whoever will buy them.

The way to evaluate a network-affiliated clinic is the same as evaluating any other: ask the questions above, evaluate the answers, verify the physician. The brand name is not the credential. The clinician is.

What good consent forms look like

A real informed consent document for a regenerative procedure should include:

A plain-language description of the procedure, in language a patient without medical training can understand.

Specific risks: infection, post-procedure flare, vasovagal reaction, the rare-but-real allergic reaction, transient nerve irritation, post-procedure pain.

Realistic expected outcomes. Some patients will not respond. Most who respond will not have complete relief. The published response rate for the indication.

Alternative treatments, including conservative care, other injections, and surgical options.

The financial terms, including what's included and what's not.

No promises. A consent document that includes language like "you will experience" or "this treatment will" rather than "you may experience" or "this treatment is intended to" is not a real consent document.

If a clinic asks you to sign something that promises results, walk away. If a clinic asks you to sign something that broadly disclaims all responsibility for outcomes regardless of negligence, also walk away. Real consents are balanced and specific.

A short checklist you can print

When you call or visit a regenerative clinic, run through these in order. If a clinic fails more than one or two, keep shopping.

1. Did you review my imaging before quoting?
2. Who is doing the injection, and what's their procedural training?
3. Is the injection ultrasound guided in real-time?
4. What's the cell source, who processed it, and what's the regulatory pathway?
5. Can I see a written protocol with cost and timeline?
6. What three indications would you refuse to treat?
7. What's your re-evaluation process if I don't respond?
8. Can you give me a fixed price in dollars for the protocol you're recommending?
9. Have you ever declined a patient who could pay? Why?
10. Will the physician answering my clinical questions today be the one doing my procedure?

What we welcome being asked

A short list, for transparency: we've answered the questions above for many patients across many consultations. We don't object to any of them. We assume that anyone serious about regenerative care is asking them of multiple clinics, and we'd rather be one of the clinics that answers cleanly than one of the clinics that gets walked away from.

If you'd like Apex to be on your shortlist, request a consultation or call (972) 768-2328. We're at 2111 Kirkwood Blvd, Suite 110b, Southlake, TX 76092. We'll review your imaging before quoting anything.

A short note from Dr. Abdullah

I started practicing in this space because I watched too many patients in my hospital practice get told by other clinics that one round of cells would solve a problem the imaging clearly said it couldn't. The biology is real. The marketing is sometimes ahead of it. If you're shopping for this kind of care, you're not being paranoid for asking hard questions. You're doing the work that the regulatory framework hasn't fully done for you yet.

Bring the questions. Ask them of every clinic you talk to, including ours. The clinic that earns your trust by answering them is more likely to be the clinic that earns your outcome.